Addressing Therapeutic Inertia in 2020 and Beyond: A 3-Year Initiative of the American Diabetes Association.

Gabbay, Robert A; Kendall, Debbie; Beebe, Christine; Cuddeback, John; Hobbs, Todd; Khan, Naeem D; Leal, Sandra; Miller, Eden; Novak, Lucia M; Rajpathak, Swapnil N; Scribner, Paul; Meneghini, Luigi; Khunti, Kamlesh

Gabbay, Robert A; Kendall, Debbie; Beebe, Christine; Cuddeback, John; Hobbs, Todd; Khan, Naeem D; Leal, Sandra; Miller, Eden; Novak, Lucia M; Rajpathak, Swapnil N; Scribner, Paul; Meneghini, Luigi; Khunti, Kamlesh.

Afiliação

Gabbay RA; American Diabetes Association, Arlington, VA.
Kendall D; Kendall Editorial, Richmond, VA.
Beebe C; Diabetes educator consultant, San Diego, CA.
Cuddeback J; American Medical Group Association, Alexandria, VA.
Hobbs T; Novo Nordisk, Plainsboro, NJ.
Khan ND; AstraZeneca, Wilmington, DE.
Leal S; Tabula Rasa HealthCare, Tucson, AZ.
Miller E; Capital Diabetes & Endocrine Associates, Silver Spring, MD.
Novak LM; Merck and Co., Kenilworth, NJ.
Rajpathak SN; Merck and Co., Kenilworth, NJ.
Scribner P; American Diabetes Association, Arlington, VA.
Meneghini L; UT Southwestern Medical Center, Parkland Health & Hospital System, Dallas, TX.
Khunti K; Diabetes Research Centre, University of Leicester, Leicester, UK.

Clin Diabetes ; 38(4): 371-381, 2020 Oct.

Article em En | MEDLINE | ID: mdl-33132507

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google